Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Expenses and Segment Operating Loss

The following table illustrates information about significant segment expenses and segment operating loss for the three months ended March 31, 2025 and 2024:

	Three Months Ended March 31,
	2025			2024
Research and development expense (1)
COVID-19 external costs (2)	$	1,234		$	39,051
HCV external costs (2)		17,584			5,953
Early stage discovery external costs (2)		331			201
Compensation and related expenses		6,037			5,675
Consulting and professional fees		519			296
Other research and development expenses		439			418
Total research and development expense		26,144			51,594
General and administrative (3)
Compensation and related expenses		2,678			2,541
Consulting and professional fees		2,939			2,585
Other general and administrative		329			500
Total general and administrative		5,946			5,626
Stock based compensation		6,951			12,586
Other segment items (4)		(4,769	)		(6,637	)
Net loss	$	(34,272	)	$	(63,169	)